Last reviewed · How we verify
ABT-348
At a glance
| Generic name | ABT-348 |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors (PHASE2)
- Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery (PHASE1)
- ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies (PHASE1)
- ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-348 CI brief — competitive landscape report
- ABT-348 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI